Taysha Gene Therapies, Inc. TSHA 深 滬
等待開盤 03-26 09:30:00 美东时间
4.58
+0.450
+10.90%
華盛通- 最 高4.59
- 今 開4.22
- 成交量 314.45万股
- 最 低 4.20
- 昨 收 4.13
- 總市值 12.55亿
- 52周最高 6.02
- 市盈率 靜 --
- 換手率 1.15%
- 52周最低 1.05
- 委 比 -96.26%
- 總股本 2.74亿
- 歷史最高 33.35
- 量 比 0.71
- 振 幅 9.44%
- 歷史最低 0.50
- 每 手 1
- 風險率 1.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Taysha Gene Therapies Q4 EPS $(0.12) Misses $(0.10) Estimate, Sales $5.485M Beat $1.889M Estimate.
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 23.71 percent. This is a 71.43 percent decrease over losses of $(0.07) per
03-19 20:02
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Taysha Gene Therapies announced it will report its 2025 full-year financial results and host a corporate update conference call on March 19, 2026. The event will include a discussion of its progress in developing AAV-based gene therapies for CNS diseases, particularly its lead program TSHA-102 for Rett syndrome. The webcast can be accessed via the company’s website.
03-12 12:00
BRIEF-Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
BRIEF-Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) March 6 (Reuters) - Taysha Gene Therapies Inc TSHA.O : TAYSHA GENE THERAPIES ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4) Source text: ID:nGNX7nQfB2 Further company coverage: TSHA.O (( Reut
03-06 21:03
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced on March 2, 2026, that its Compensation Committee granted restricted stock units (RSUs) representing 156,870 shares and an option to purchase 134,460 shares of common stock to a new employee under the 2023 Inducement Plan. The RSUs vest每年四次，为期四年，股票期权的行权价为$4.53，为期十年，按照与服务期限相符的条件归属。Taysha专注于开发用于中枢神经系统罕见单基因疾病的腺相关病毒（AAV）基因疗法，其领先项目TSHA-102正在针对Rett综合征进行研究...
03-06 13:00
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
Needham Reiterates Buy on Taysha Gene Therapies, Maintains $10 Price Target
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $10 price target.
03-03 19:00
Taysha Gene Therapies Grants 349,000 RSUs to New Employees
Taysha Gene Therapies Grants 349,000 RSUs to New Employees Taysha Gene Therapies Inc. has granted three new employees a total of 349,000 restricted stock units (RSUs) as part of their employment agreements. The RSUs will vest in four equal annual installments starting on the first anniversary of the
02-06 21:00
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 6, 2026 — Taysha Gene Therapies, Inc. announced that its Compensation Committee granted 349,000 restricted stock units (RSUs) to three new employees on February 2, 2026, under the 2023 Inducement Plan. The RSUs vest over four years, contingent on continued employment. Taysha is a clinical-stage biotech company advancing AAV-based gene therapies for severe CNS monogenic diseases.
02-06 13:00
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
